|Table of Contents|

Clinical study of low-dose chest CT plain scan in screening early lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 03
Page:
407-409
Research Field:
Publishing date:

Info

Title:
Clinical study of low-dose chest CT plain scan in screening early lung cancer
Author(s):
WANG Liping; DUAN Yingjia; HOU Jian; ZHAI Fulin
Department of Oncology，the First People's Hospital of Chenzhou City，Hunan Chenzhou 423000，China.
Keywords:
low-dose chest CT; lung cancer; gene detection
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.03.009
Abstract:
Objective：To explore the application effect and value of low-dose CT (LDCT) chest plain scan in screening early lung cancer in physical examination.Methods：1 100 cases of low-dose chest CT and 750 cases of chest X-ray irradiation were collected from January to December 2018 in our hospital.Results：Compared with chest X-ray，low-dose chest CT showed that the proportion of pulmonary nodule focus，positive pulmonary nodule and diagnosed lung cancer was statistically significant (P<0.05).In the low-dose CT group，the proportion of patients with lung adenocarcinoma was 90%,accounts for 40% in women，60% in men，60% in patients over 50 years old and 42.5% of them were positive for driving gene.Conclusion：Compared with chest radiograph，low-dose CT has a high detection rate of malignant tumor，which is an early screening method for lung cancer.

References:

［1］ZHENG R，ZENG H，ZHANG S，et al.Lung cancer incidence and mortality in China，2010［J］.Thorac Cancer，2014，5(4)：330-336.
［2］CHEN W，ZHENG R，BAADE PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132.
［3］郑荣寿，孙可欣，张思维,等.2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志，2019，41（1）：19-28. ZHENG RS,SUN KX，ZHANG SW，et al.Analysis of cancer prevalence in China in 2015［J］.Chinese Journal of Cancer，2019，41(1)：19-28.
［4］张晓菊.肺结节诊治中国专家共识（2018版）解读［J］.中华实用诊断与治疗杂志,2019,1(33):1-3. ZHANG XJ.Interpretation of the consensus of Chinese experts on the diagnosis and treatment of pulmonary nodules(2018 Edition)［J］.J Chin Practic Diagn Ther，2019，1(33):1-3.
［5］MICHAEL C，KATHLEEN T，CARLY W，et al.International early lung cancer action program：Update on lung cancer screening and the management of CT screen-detected findings［J］.AMJ Medical Journal,2017，2(8):1-15.
［6］FERLAY J，SOERJOMATARAM I，DIKSHIT R，et al.Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012［J］.Int J Cancer，2015，136(5)：E359-E386.
［7］National Lung Screening Trial Research Team，ABERLE DR，BERG CD，et al.The national lung screening trial：Overview and study design［J］.Radiology，2011，258(1)：243-253.
［8］National Lung Screening Trial Research Team，ABERLE DR，ADAMS AM，et al.Reduced lung-cancer mortality with low-dose computed tomographic screening［J］.N Engl J Med，2011，365(5)：395-409.
［9］张佩佩，赵君慧.女性肺癌的临床特征及治疗策略［J］.现代肿瘤医学，2020，28(07)：1217-1221. ZHANG PP，ZHAO JH.Clinical characteristics and treatment strategy of female lung cancer［J］.Modern Oncology，2020，28(07)：1217-1221.
［10］KRISTIANSEN C，SCHYTTE T，HANSEN KH，et al.Trends in lung cancer in elderly in Denmark，1980-2012［J］.Acta Oncologica，2016,55：46-51.
［11］PAZ-ARES LG，DE MARINIS F，DEDIU M，et al.Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer(PARAMOUNT)：A double-blind，phase 3，randomised controlled trial［J］.Lancet Oncol，2012，13(3)：247-255.
［12］CHEN JD，HERRINGTON PJ，GODLEY A，et al.Emergent therapies and EGFR mutation testing in non-small cell lung cancer：Real-world practices［J］.Value in Health，2018，21(1)：S41.
［13］MICHAEL O，ROBERT H CHRISTENSON，JULA B，et al.Plasma EGFR mutation testing in non-small cell lung cancer：A value proposition［J］.Clinica Chimica Acta，2019，8(495):481-486.
［14］OSMANI L，ASKIN F，GABRIELSON E，et al．Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma(NSCLC)：Moving from targeted therapy to immunotherapy［J］.Semin Cancer Biol，2018，52(1)：103-109.
［15］SOCINSKI MA，BONDARENKO I，KARASEVA NA，et al.Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer：Final results of a phase Ⅲ trial［J］.J Clin Oncol，2012，30(17)：2055-2062.
［16］SEONGGYU B，BORAM L，WOONG-YANG,et al.Benefit of targeted DNA sequencing in advanced non-small-cell lung cancer patients without EGFR and ALK alterations on conventional tests［J］.Clinical Lung Cancer，2020,21(3):e182-e190.

Memo

Memo:
湖南省科技创新计划项目（编号：2018JJ3016）;湘南学院课题项目（编号：2016XJ63）
Last Update: 2020-12-31